Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Study of Experimental Drug (Axitinib) in Patients with Metastatic Pheochromocytoma (PCC) or Paraganglioma
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAR5314
U.S. Govt. ID: NCT03839498
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: Axitinib (AG-013736) is an investigational (experimental) drug that is being studied in patients with metastatic pheochromocytoma/paraganglioma. The main goal of this study is to find out if axitinib is able to stop tumors from growing, or shrink tumors in patients with this type of cancer.
This study is closed
Antonio Fojo, MD, PhD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with pheochromocytoma or paraganglioma? Yes No
Do you have a life expectancy of at least 3 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator